Skip to main content

Advertisement

ADVERTISEMENT

Current Research

Hyaluronic Acid as a Treatment Option for Pressure Ulcers

December 2013
1044-7946
WOUNDS. 2013;25(12):328-332.

Abstract

Introduction. Health care professionals are constantly seeking novel approaches to treat pressure ulcers because of the impact they have on patient quality of life and health, as well as the costs associated with treating them. Methods. A review of the literature from 2002-2012 was conducted on the clinical usefulness of hyaluronic acid in tissue regeneration. Reports suggest that the therapeutic use of hyaluronic acid favors tissue regeneration by modulating the hydration and osmotic balance. Results. Different studies show that hyaluronan and derived-hyaluronic acid products are safe and free of adverse effects. Furthermore, a few studies examine the hyaluronic acids repercussions in pressure ulcer treatment. Conclusion. Reports suggest that this molecule could be successfully used to treat pressure ulcers in association with conventional measures. 

Introduction

 Pressure ulcers (PUs) are skin lesions that may involve the epidermis and deeper layers of the skin, sometimes even causing damage to muscle or bone. Triggering factors include an increase in capillary pressure at skin level as a consequence of the action of 2 opposing forces, as in the case of pressure on a bone protuberance.1 Pressure ulcers compromise the health and quality of life of patients and entail high economic costs. Patients with a single PU are 3.5 to 5 times more likely to stay in the hospital than patients without an ulcer, and the development of novel approaches is of great interest to health care professionals, especially the nurses, who often treat them.2   Pressure ulcers are currently treated with a moist environment, which high-level evidence has proved effective in reducing healing time.3 Hyaluronic acid is one of a group of molecules proposed to participate in the pathophysiological mechanisms underlying wound healing.4 More recent studies have shown that treatment with hyaluronic acids and their derivatives have an important role in the regeneration of various tissues, such as periodontal, bone, adipose, or cartilage regeneration.5-7   The objective of this study was to review published reports on the clinical usefulness of hyaluronic acid in tissue regeneration and PU healing.

Material and Methods

  Literature searches were carried out using the dialog interface in the following databases: PubMed and CINAHL. Databases were searched from 2002 through 2012 for human studies. The following key words were covered in the search strategy: “hyaluronic acid,” “pressure ulcers,” “pressure sores,“ “hyaluronic acid and pressure ulcers,” and “hyaluronic acid and pressure sores.” Titles and abstracts identified by the literature searches were read and reviewed. Those not appearing to meet key words were excluded and the others were reviewed in full.

Results

  Hyaluronic acid is a natural biopolymer with a highly preserved molecular structure among mammal species. It was first reported in 1934 and was subsequently synthesized in the laboratory.8 It is a natural polymer of disaccharides, which are composed of alternating D-glucuronic acid and D-N-acetylglucosamine, linked together via alternating β-1,4 and β-1,3 glycosidic bonds. One of the components of the extracellular matrix, hyaluronic acid is present in skin, cartilage, bone, and brain, among other tissues. It has proved valuable in neurosurgery and dermatology because hyaluronic acid and degradation products can modulate wound healing.8 Numerous studies have demonstrated the usefulness of hyaluronic acid in skin lesions and cartilage defects, in glial cell culture, and in the regeneration/increase of sperm motility.8 Over the past few years, there has been a considerable increase in the use of hyaluronic acid in aesthetic plastic surgery.9 Physiologically, the key characteristic of this molecule is its high hydroscopicity, which serves to regulate tissue hydration and osmotic balance. It is also water soluble, enabling the formation of an easily handled and applied gel.10 In recent years, hyaluronic acid and its sodium salt have been applied for multiple clinical purposes.11,12

Discussion

  Usefulness of hyaluronic acid and its sodium salt in tissue regeneration. The usefulness of hyaluronic acid and its derivatives in tissue regeneration, tissue engineering, epidermal diseases, ophthalmic surgery, and plastic surgery is well documented.9,11-14 Although the action mechanism of this molecule in tissue regeneration has not been fully elucidated, effects have generally been attributed to its lubricating, hydroscopic, and homeostatic properties.15 It can also interact with a number of receptors, activating a cascade of signals that influence gene migration, proliferation, and expression at the extracellular matrix level.15   Hyaluronic acid and its sodium salts are used for wound healing. One explanation for its positive effect is that collagen deposited by fibroblasts is a key factor in tissue reconstruction, and hyaluronic acid has been found to stimulate fibroblast proliferation in both in vivo and in vitro studies.16 There is also evidence of an increase in extracellular matrix remodeling and an improved organization of collagen deposits after the application of hyaluronic acid.17 Moreover, the degradation products of hyaluronic acid are proangiogenic and can modulate the production of hyaluronic acid by fibroblasts, which is regulated by a large number of growth factors.18 Finally, hyaluronic acid also favors tissue regeneration by increasing keratinocyte proliferation and mobility.19,20   A major advantage in the clinical setting of hyaluronic acid and its salts is that it has very few adverse effects, with only isolated reports of inflammation and hypersensitivity.21-23 Hyaluronic acid is currently considered a useful resource in tissue regeneration.5   Pressure ulcers. Pressure ulcers are lesions of ischemic origin on the skin and underlying tissue with loss of cutaneous substance. They are produced by prolonged pressure or friction between a hard surface of the patient and a hard surface in contact with the patient. Care guidelines in numerous institutions classify 3 primary types of risk factors for PU formation: pressure, friction, and shear.24 Pressure ulcers are most frequently observed at bone protuberances, when the soft tissue has been compressed against an external surface. Tissue hypoxia produces rapid tissue degeneration in the area, which can range widely between a mild skin reddening and deep ulcers involving muscle or even bone.1,3   The prevalence of PUs in Spain increased between the first National PU Survey in 200125 and the second in 200526 from to 8.34% to 9.11% of primary care patients receiving home care; 8.81% to 8.91% of hospitalized patients; and 7.6% to 10.9% of patients in residences for the elderly. This high prevalence is associated with major economic repercussions, as detailed in numerous studies worldwide.27,28   The moist healing procedure has demonstrated the best outcomes to date.29,30 However, there have been wide investigations on alternative treatments to deliver more rapid tissue regeneration, including the utilization of growth factors and platelets and of autologous growth factor- and platelet-rich plasma.31-35   Pressure ulcers and hyaluronic acid. Hyaluronic acid has long been used to regenerate damaged tissue, but few data are available on its use to treat PUs. A biopsy study found significantly lower hyaluronic acid levels in tissue samples from chronic PUs than in samples from open skin wounds, and lower levels in both compared to healthy tissue samples.15 This may be related to depolymerization of hyaluronic acid due to the higher hyaluronidase activity and presence of reactive oxygen species (free radicals) in the inflammatory response.36 Further studies reported the use of sodium hyaluronate and iodine complex in patients with diabetic foot problems. This treatment was effective in the majority of the patients with diabetes. The local treatment did not produce side effects or allergic reaction.37 Barrois et al38 investigated the efficacy and tolerability of hyaluronan (hyaluronic acid) treatment over 3 weeks in 21 patients with PUs. The results showed tolerability and efficacy of this treatment was good or very good, depending on the reduction of surface area, the presence of granulation tissue, and the decrease of fibrous tissue. A recent study determined the usefulness of combining hyaluronic acid and argentic sulphadiazine in the treatment of PUs.39 Paghetti et al39 found that improvement or complete healing of PUs was observed in 67% of patients at early follow-up (10 days), increasing to 76% and 87% at 20 and 35 days, respectively.39 Hyaluronic acid has also been used as an active wound dressing.40 Zavan et al40 described the utility of porous nanoparticles of hyaluronan enriched with growth factors in the treatment of PUs. Other studies showed the efficacy of a 3-dimensional, polymerized hyaluronic acid as a biologic medicated dressing.41,42 Recently, a new formulation of hyaluronic acid (lysine-hyaluronate) has been studied to treat decubitus ulcers. The results obtained in a double-blind randomized study showed a greater reduction of the ulcer size treated with lysine-hyaluronate vs the commonly used sodium hyaluronate.43

Conclusion

  More effective treatment options are required for PUs due to their elevated prevalence, negative impact on quality of life of patients, and high associated costs. There is wide scientific evidence on the positive role of hyaluronic acid and its sodium salts in tissue regeneration and wound healing. It maintains wound hydration and may neutralize the excess hyaluronidase in lesions and eliminate free radicals. High efficacy of hyaluronic acid was proven, particularly in the treatment of diabetic ulcers. Its use when treating PUs resulted in reduction of the ulcer size and a good tolerability and efficacy, but few data are available on its use to treat these wounds. Further research is warranted into the utilization of hyaluronic acid and related substances for PUs.

Acknowledegments

The authors are from the Department of Nursing, Faculty of Health Sciences, University of Granada, Granada, Spain. Concepción Ruiz, PhD is from the Department of Nursing, Faculty of Health Sciences, University of Granada, Granada, Spain; and Neuroscience Institute, University of Granada, Granada, Spain.

Address correspondence to: Concepción Ruiz Faculty of Health Sciences University of Granada Avda de Madrid s/n 18071-Granada (Spain) crr@ugr.es

Disclosure: The authors disclose no financial or other conflicts of interest.

References

1. Defloor T. The risk of pressure sores: a conceptual scheme. J Clin Nurs. 1999;8(2):206-216. 2. Childress B, Stechmiller J, Schultz G. Arginine metabolites in wound fluids from pressure ulcers: a pilot study. Biol Res Nurs. 2008;10(2):87-92. 3. Bours GJ, Halfens RJ, Abu-Saad HH, Grol RT. Prevalence, prevention, and treatment of pressure ulcers: descriptive study in 89 institutions in the Netherlands. Res Nurs Health. 2002;25(2):99-110. 4. Werner S, Grose, R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83(3):835-870. 5. Bansal J, Kedige S, Anand S. Hyaluronic acid: A promising mediator for periodontal regeneration. Indian J Dent Res. 2010;21(4):575-578. 6. Kang SW, Kim JS, Park KS, et al. Surface modification with fibrin/hyaluronic acid hydrogel on solid-free form-based scaffolds followed by BMP-2 loading to enhance bone regeneration. Bone. 2011;48(2):298-306. 7. Toh WS, Lee EH, Guo XM, et al. Cartilage repair using hyaluronan hydrogel-encapsulated human embryonic stem cell-derived chondrogenic cells. Biomaterials. 2010;31(27):6968-6980. 8. Prince RD, Berry MG, Navsaria HA. Hyaluronic acid: the scientific and clinical evidence. J Plast Reconstr Aesthet Surg. 2007;60(10):1110-1119. 9. Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acids (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult females subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg. 2003;29(8):802-809. 10. Beasley KL, Weiss MA, Weiss RA. Hyaluronic acid fillers: a comprehensive review. Facial Plast Surg. 2009;25(2):86-94. 11. Saito S, Furuya T, Kotake S. Therapeutic effects of hyaluronate injections in patients with chronic painful shoulder: A meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken). 2010;62(7):1009-1018. 12. Vogel R, Crockett RS, Oden N, Laliberte TW, Molina L; Sodium Hyaluronate Ophthalmic Solution Study Group. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena). Am J Ophthalmol. 2010;149(4):594-601. 13. Pasonen-Seppänen S, Karvinen S, Törrönen K, et al. EGF upregulates, whereas TGF-beta down regulates, the hyaluronan synthases Has2 and Has3 in organotypic keratinocyte cultures: correlations with epidermal proliferation and differentiation. J Invest Dermatol. 2003;120(6):1038-1044. 14. Pavesio A, Abatangelo A, Borrione A, et al. Hyaluronan-based scaffolds (Hyalograft C) in the treatment of knee cartilage defects: preliminary clinical findings. Novart Found Symp. 2003;249:203-217. 15. Dechert TA, Ducale AE, Ward SI, Yager DR. Hyaluronan in human acute and chronic dermal wounds. Wound Repair Regen. 2006;14(3):252-258. 16. Mesa F, Aneiros J, Cabrera A, et al. Antiproliferative effect of topic hyaluronic acid gel. Study in gingival biopsies of patients with periodontal disease. Histol Histopathol. 2002;17(3):747-753. 17. Iocono JA, Krummel TM, Keefer K, Allison GM, Paul H. Repeated additions of hyaluronan alters granulation tissue deposition in sponge implants in mice. Wound Repair Regen. 1998;6(5):442-448. 18. Heldin P, Laurent TC, Heldin CH. Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts. Biochem J. 1989;258(3):919-922. 19. Lin G, Stern R. Plasma hyaluronidase (Hyal-1) promotes tumor cell cycling. Cancer Lett. 2001;163(1):95-101. 20. Moore A. Hyaluronan: a review of the recent patent literature. Drugs. 2000;3(2):198-201. 21. Friedman PM, Mafong EA, Kauvar AN, Geronemus RG. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg. 2002;28(6):491-494. 22. Lowe NJ, Maxwell CA, Patnaik, R. Adverse reactions to dermal fillers: review. Dermatol Surg. 2005;31(11 Pt 2):1616-1625. 23. Leonhardt JM, Lawrence N, Narins RS. Angioedema acute hypersensitivity reaction to injectable hyaluronic acid. Dermatol Surg. 2005;31(5):577-579. 24. European Pressure Ulcer Advisory Panel and National Pressure Ulcer Advisory Panel. Prevention and treatment of pressure ulcers: quick reference guide. Washington, DC: National Pressure Ulcer Advisory Panel; 2009. 25. Rueda López J, Torra i Bou J, Cuervo FM, Verdú Soriano J, Soldevilla Agreda J. 1er estudio nacional de prevalencia y tendencias de prevención de upp en España: epidemilogía y variables definitorias de las lesiones y pacientes. Gerokomos. 2003;14(1):37-47. 26. Soldevilla-Agreda J, Torra-i-Bou J. Epidemiología de las úlceras por presión en España. Estudio piloto en la comunidad autónoma de la Rioja. Gerokomos. 1999;10(2):75-86. 27. Schuurman JP, Schoonhoven L, Defloor T, van Engelshoven I, van Ramshorst B, Buskens E. Economic evaluation of pressure ulcer care: a cost minimization analysis of preventive strategies. Nurs Econ. 2009;27(6):390-400. 28. Graves N, Birrell F, Whitby M. Effect of pressure ulcers on length of hospital stay. Infect Cont Hosp Ep. 2005;26(3):293-297. 29. García Fernández FP, Pancorbo Hidalgo PL, Verdú Soriano J, et al. Eficacia de los productos para el tratamiento de las úlceras por presión: una revisión sistemática con metaanálisis. Gerokomos. 2007;18(1):36-48. 30. Vanderwee K, Clark M, Dealey C, Gunningberg L, Delfoor T. Pressure ulcer prevalence in Europe: a pilot study. J Eval Clin Pract. 2007;13(2):227-235. 31. Herouy Y, Mellios P, Bandemir E, et al. Autologous platelet-derived wound healing factor promotes angiogenesis via αvβ3 integrin expression in chronic wounds. Int J Mol Med. 2000;6(5):515-519. 32. Stacey MC, Mata SD, Trengove NJ, Mather Ca. Randomised double-blind placebo controlled trial of topical autologous platelet lysate in venous ulcer healing. Eur J Vasc Endovasc Surg. 2000;20(3):296-301. 33. Tarroni G, Tessarin C, De Silvestro L, et al. Local therapy with platelet-derived growth factors for chronic diabetic ulcers in haemodialysis patients [in Italian]. G Ital Nefrol. 2002;19(6):630-633. 34. Anitua E, Aguirre JJ, Algorta J, et al. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B Appl Biomater. 2008;84(2):415-421. 35. Ramos Torrecillas J, De Luna-Bertos E, García-Martínez O, Díaz-Rodríguez L, Ruiz C. Use of platelet-pich plasma to treat pressure ulcers: a Case Study. J Wound Ostomy Cont Nurs. 2013;40(2):198-202. 36. Agren UM, Tammi RH, Tammi MI. Reactive oxygen species contribute to epidermal hyaluronan catabolism in human skin organ culture. Free Radical Biol Med. 1997;23(7):996-1001. 37. Sobotka L, Smahelova A, Pastorova J, Kusalova M. A case report of the treatment of diabetic foot ulcers using a sodium hyaluronate and iodine complex. Int J Low Extrem Wounds. 2007;6(3):143-147. 38. Barrois B, Carles M, Rumeau M, et al. Efficacy and tolerability hyaluronan (ialuset) in the treatment of pressure ulcers: a multicentre, non-randomised, pilot study. Drugs R D. 2007;8(5):267-273. 39. Paghetti A, Bellingeri A, Pomponio G, Sansoni J, Paladino D. Topic efficacy of ialuronic acid associated with argentic sulphadiazine (Connettivina Plus) in the treatment of pressure sores: a prospective observational cohort study [in Italian]. Prof Inferm. 2009;62(2):67-77. 40. Zavan B, Vindigni V, Vezzù K, et al. Hyaluronan based porous nano-particles enriched with growth factors for the treatment of ulcers: a placebo-controlled study. J Mater Sci Mater Me. 2009;20(1):235-247. 41. Chiummariello S, Arleo S, Alfano C. Il trattamento topico di ulcere da pressione con aminoacidi e acido ialuronic. Caso clinico. G Chir. 2010;31(5):251-255. 42. Cervelli V, De Angelis B, Lucarini L, et al. Tissue regeneration in loss of sustance on the lower limbs through use of platelet-rich plasma, stem cells from adipose tissue, and hyaluronic acid. Adv Skin Wound Care. 2010;23(6):262-272. 43. Felzani G, Spoletini I, Convento A, et al. Effect of lysine hyaluronate on the healing of decubitus ulcers in rehabilitation patients. Adv Ther. 2011;28(5):439-445.

Advertisement

Advertisement

Advertisement